Monday, March 2, 2009
Genentech: A Robust Future or Last Hurrah?
Genentech chairman and CEO Art Levinson and his executive team got a wintry day in Manhattan to make their case to investors that Roche is lowballing the company with its $86.50 hostile tender offer for the shares of the company it doesn't already own. Despite projections of a [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment